Serum Institute applies for emergency use authorisation for COVID-19 vaccine
Follow The Hawk on Google News+ FollowAdvertisement
New Delhi: Vaccine manufacturing major Serum Institute of India (SII) on Monday said it has applied to Drugs Controller General of India (DCGI) for emergency use authorisation for its COVID-19 vaccine Covishield.
The Pune-based company has collaborated with Oxford University and pharmaceutical company Astra Zeneca for making the vaccine and is conducting trials in India.
Advertisement
"As promised, before the end of 2020, @SerumInstIndia has applied for emergency use authorisation for the first made-in-India vaccine, Covishield," SII CEO Adar Poonawala said in a tweet.
Also readFSSAI to initiate action against Bisleri over unsafe water sample
He further said: "This will save countless lives, and I thank the Government of India and Sri @narendramodi ji for their invaluable support."
Last week, Pfizer India said it has applied to India's drug regulator DCGI for emergency-use authorisation for its COVID-19 vaccine, after the company's parent received clearance for the treatment from Britain and Bahrain.
—PTI
Get The Hawk first on Google
Add The Hawk as a preferred source and Google shows you more of our stories in Top Stories. Follow us on Google News too.
Advertisement








